Multi-antigen coronavirus vaccine induces potent and durable cross-protection against multiple SARS-CoV-2 variants
npj Vaccines·
- DOI
- 10.1038/s41541-026-01549-y
- PMID
- —
- PMCID
- —
- OpenAlex
- W7203695392
- Study type
- Journal article
- Publisher
- Springer Science and Business Media LLC
- Article type
- journal-article
- Integrity
- current
Why this research matters now
The reported durability and breadth of the cellular response suggest a potential strategy to overcome the immune evasion and waning protection associated with current spike-focused immunizations.
Structured evidence summary
Research question
Whether integrating highly conserved non-Spike coronavirus proteins into an immunization strategy generates sustained, broad-spectrum cellular immunity capable of neutralizing diverse viral variants.
Study design
A peer-reviewed preclinical investigation utilizing a golden Syrian hamster model to evaluate the immunogenicity and protective efficacy of a novel multi-antigen vaccine candidate.
Population and setting
Experimental testing was conducted in golden Syrian hamsters, while initial antigen selection relied on T cell reactivity profiles observed in unvaccinated individuals who experienced asymptomatic SARS-CoV-2 infection.
Main findings
Administration of three conserved non-Spike proteins stimulated substantial populations of lung-resident and cytotoxic T cells, diminished clinical symptoms and viral replication across multiple variants, augmented baseline spike-targeted mRNA immunization, and maintained these benefits for over a year.
Public-health relevance
The reported durability and breadth of the cellular response suggest a potential strategy to overcome the immune evasion and waning protection associated with current spike-focused immunizations.
Important limitations
The evaluation depends entirely on a rodent model, so direct extrapolation to human outcomes requires formal clinical verification.
GIDS interpretation
This record documents early-stage laboratory data regarding an alternative vaccination approach targeting evolutionarily stable coronavirus proteins, offering contextual information for academic tracking of novel immunogen development rather than reflecting real-world deployment metrics.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 9 auditable classifier relationships to diseases, places, topics, and study design.